CW Advisors LLC Has $5.15 Million Holdings in Medtronic PLC $MDT

Key Points

• CW Advisors LLC increased its stake in Medtronic PLC by 79.2%, owning 57,309 shares valued at over $5 million as of the latest SEC filing.
• Medtronic recently announced a quarterly dividend of $0.71, yielding 3.1%, with a dividend payout ratio of 78.24%.
• The company's latest earnings report showed a 7.7% increase in quarterly revenue, reaching $8.58 billion, surpassing analysts' expectations.

CW Advisors LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 79.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,309 shares of the medical technology company's stock after acquiring an additional 25,320 shares during the period. CW Advisors LLC's holdings in Medtronic were worth $5,151,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Dunhill Financial LLC raised its stake in shares of Medtronic by 17.2% in the 1st quarter. Dunhill Financial LLC now owns 847 shares of the medical technology company's stock worth $76,000 after buying an additional 124 shares in the last quarter. Cidel Asset Management Inc. raised its stake in shares of Medtronic by 1.3% in the 1st quarter. Cidel Asset Management Inc. now owns 9,531 shares of the medical technology company's stock worth $856,000 after buying an additional 126 shares in the last quarter. Petros Family Wealth LLC raised its stake in shares of Medtronic by 4.3% in the 1st quarter. Petros Family Wealth LLC now owns 3,111 shares of the medical technology company's stock worth $280,000 after buying an additional 127 shares in the last quarter. Motco raised its stake in shares of Medtronic by 27.0% in the 1st quarter. Motco now owns 635 shares of the medical technology company's stock worth $57,000 after buying an additional 135 shares in the last quarter. Finally, Baker Avenue Asset Management LP raised its stake in shares of Medtronic by 3.1% in the 1st quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company's stock worth $410,000 after buying an additional 136 shares in the last quarter. Institutional investors own 82.06% of the company's stock.

Insider Buying and Selling

In other news, Director William R. Jellison bought 2,500 shares of the stock in a transaction on Monday, August 25th. The shares were purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company's stock, valued at $461,850. This trade represents a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on MDT shares. Wells Fargo & Company boosted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 20th. Mizuho lifted their target price on Medtronic from $98.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. UBS Group lifted their target price on Medtronic from $94.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 20th. William Blair upgraded Medtronic to a "hold" rating in a report on Friday, July 11th. Finally, Evercore ISI lifted their target price on Medtronic from $103.00 to $106.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $102.14.

Medtronic Stock Down 0.1%

Shares of MDT stock traded down $0.08 on Thursday, reaching $91.97. 3,728,111 shares of the company's stock traded hands, compared to its average volume of 7,666,188. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $96.25. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.42 and a current ratio of 1.85. The company has a market capitalization of $117.98 billion, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 2.34 and a beta of 0.80. The business's 50 day moving average price is $90.06 and its two-hundred day moving average price is $88.06.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.56% and a net margin of 13.63%.The business had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. Medtronic's revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.1%. Medtronic's payout ratio is 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.